Nkarta Inc (NKTX)
7.03
+0.12
(+1.74%)
USD |
NASDAQ |
Jul 26, 16:00
7.03
0.00 (0.00%)
After-Hours: 20:00
Nkarta Research and Development Expense (Annual): 96.77M for Dec. 31, 2023
Research and Development Expense (Annual) Chart
Historical Research and Development Expense (Annual) Data
Date | Value |
---|---|
December 31, 2023 | 96.77M |
December 31, 2022 | 90.90M |
December 31, 2021 | 63.41M |
Date | Value |
---|---|
December 31, 2020 | 36.22M |
December 31, 2019 | 17.22M |
December 31, 2018 | 4.252M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Annual) Range, Past 5 Years
17.22M
Minimum
2019
96.77M
Maximum
2023
60.90M
Average
63.41M
Median
2021
Research and Development Expense (Annual) Benchmarks
AngioDynamics Inc | 31.51M |
UnitedHealth Group Inc | -- |
Allogene Therapeutics Inc | 242.91M |
Century Therapeutics Inc | 92.71M |
Cullinan Therapeutics Inc | 148.16M |